Novel SARS-CoV-2 vaccine candidates: Live, recombinant Leishmania

NIH Pandemic-Era Grants

Pandemic Era Grants

2023

↗ Live URL (may be dead)

Document text

Principal Investigator: David  Sacks
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2023
Award: $114,312
Funding agency: National Institute of Allergy and Infectious Diseases

Our initial experiments involving the transgenic L. major lines overexpressing spike protein, either the full length S gene sequence or secreted S1/S2 subunits, showed that in each case the clones were attenuated in mice. New transgenic lines were generated:  the full length S gene sequence was amplified by PCR from plasmid pCAGGS containing the Wuhan-Hu-1 spike  and inserted into plasmid pSSU-NEO  using a Gibson Assembly reaction, with the addition of an N-terminal myc tag and a C-terminal HA tag to evaluate spike cleavage into two subunits (S1 and S2) by potential Leishmania proteases. The generated plasmid pSSU-fullS was then linearized with PmeI and PacI enzymes and the purified construct was integrated into Leishmania major Fn strain by transfection (4D-Nucleofector, Lonza). Positive transfectants were selected by geneticin (G418) antibiotic resistance. Expression of SARS CoV-2 spike was confirmed by Western Blotting using anti-myc and anti-HA antibodies in the three clones tested. Full-length spike protein was detected at expected band size (143 kDa) on blots for all clones of L. major transfectants but not in the wild-type (WT) culture samples. 
Ten thousand metacyclic promastigotes purified from WT L. major or Spike-L. major cultures were inoculated intradermally into both C57BL/6J mice ears.   The full length Spike-L. major line and the S1/S2 secreting lines again failed to  induce any visible ear lesions while the WT control  produced ulcerated lesions.   The attenuated recombinant parasites were again present in the ear at numbers that were not significantly reduced compared to the wild type strain or to a control recombinant strain expressing ovalbumin.     The lymph nodes from the LmSpike-infected mice contained a higher frequency of spike-specific IFNg+ CD4+ T cells compared to the WT-infected mice, although the frequencies were relatively low (spike L. major - 3.7% of CD4+ T cells were IFNg+ vs 0.52% for wt L. major).  A PE-labeled peptide MHC Class 1 tetramer containing the dominant H-2K(b) spike epitope was used for detection of spike-specific CD8+ T cells in the infected mice.   The frequencies of tetramer positive CD8+ T cells were not increased in either the ears or ear draining lymph nodes of mice infected with Spike-L. major compared to Wt L. major.   Thus, mice infected with the transgenic parasites fail to mount a strong spike specific T cell response.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><Africa><Antibiotic Resistance><Antibodies><Antigenic Determinants><Attenuated><Binding Determinants><C-terminal><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID-19 S protein><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 virus><COVID19 S protein><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><Cell Mediated Immunology><Cell-Mediated Immunity><Cellular Immunity><CoV-2><CoV2><Detection><Disease><Disorder><Dose><Ear><Enzyme Gene><Enzymes><Epitopes><Esteroproteases><Face><Frequencies><G-418><G418><Generations><Genes><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Geneticin><Human><Immune response><Immunoblotting><Immunological response><Label><Leishmania><Leishmania (Leishmania) major><Leishmania major><Leishmania tropica major><Length><Lesion><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Mice><Mice Mammals><Middle East><Modern Man><Murine><Mus><N-terminal><NH2-terminal><Ovalbumin><Parasites><Parasitic infection><Peptidases><Peptide Hydrolases><Peptide-MHC><Peptide-Major Histocompatibility Protein Complex><Peptide/MHC Complex><Plasmids><Protease Gene><Proteases><Protein Subunits><Proteinases><Proteins><Proteolytic Enzymes><Reaction><Recombinant DNA Technology><Recombinant Vaccines><Recombinants><Resistance to antibiotics><Resistant to antibiotics><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><System><T cell response><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><Testing><Transfection><Transgenic Organisms><Vaccines><Western Blotting><Western Immunoblotting><Wuhan coronavirus><antibiotic G 418><antibiotic drug resistance><antibiotic resistant><arm><attenuate><attenuates><corona virus disease 2019 vaccine><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><draining lymph node><experiment><experimental research><experimental study><experiments><faces><facial><genetically engineered><hCoV19><host response><immune system response><immunization strategy><immunoresponse><lymph gland><lymph nodes><lymphnodes><mouse model><murine model><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><novel><overexpress><overexpression><pMHC><parasite infection><pre-clinical development><preclinical development><protein blotting><regional lymph node><transgenic><vaccination strategy><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus>